Background: Cost-effectiveness or value of cardiovascular therapies may be undermined by unwarranted cost variation, particularly for heterogeneous procedures such as catheter ablation for atrial fibrillation (AF). We sought to characterize cost variation of AF ablation in the US healthcare system and the relationship between cost and outcomes.
INTRODUCTION
The US healthcare system is the most expensive in the world, utilizing 17.7% of the 2011 national gross domestic product. 1, 2 Geographic variation has previously been observed in both Medicare 3, 4 and private insurance 5 per patient spending. Facility and geographic variation in disease management of cardiovascular conditions has been reported principally for heart failure and myocardial infarction, with most data coming from the Veterans Health Administration. 6, 7 In atrial fibrillation (AF), catheter ablation has become an increasingly popular and widespread procedure for restoration of sinus rhythm and is endorsed by multiple professional society guidelines. 8, 9 However, the procedure is highly heterogeneous, relying on a wide variety of techniques, equipment, time, and resources. For example, AF ablation could be performed using a variety of different ablation and mapping catheters, mapping systems, ablation energy sources, sedation strategies, and ablation strategies. In this context, the variation in cost of AF ablation or its relationship to outcomes and subsequent healthcare utilization has not been defined. We therefore sought to retrospectively describe the cost variation of catheter ablation for AF at the patient and the facility level by using US commercial claims and cost data. We then sought to evaluate the relationship between AF ablation cost and subsequent healthcare utilization.
METHODS
We performed a retrospective cohort study from the Truven Health Ablation facility was coded using an encrypted 5-digit zip code, allowing for all ablations performed within a single zip code to be aggregated, while maintaining provider and institution anonymity. We resolved instances of multiple zip codes associated with a patient's ablation encounter by choosing the zip code with the single largest associated cost (likely representing the ablation procedure itself).
We excluded patients whose ablation was not paired with a unique encrypted zip code, whose ablation cost less than $1,000, and ablation facilities with less than 10 total ablations performed. We required continuous insurance enrollment from 6 months prior to 1 year after the ablation to allow time for patient baseline characteristics to be captured as well as for patients without adequate follow-up to be excluded.
We totaled all reimbursement payments, which included physician fees, associated with an ablation encounter to determine encounter cost. This method captures actual costs (not charges), thereby avoiding issues with estimating cost-to-charge ratios that are dependent on treatment facility and payer. These methods have been widely applied in health economics assessments for cardiovascular procedures and for AF ablation specifically. 10 
RESULTS
The cohort included 9,415 patients across 327 ablation facilities ( Figure 1 ). Of these patients, 4,885 were outpatients (57.9 ± 10.3 years; 27.3% female) across 316 ablation facilities and 4,530
were inpatients (59.7 ± 10.6 years; 29.5% female) across 316 ablation facilities. Baseline patient characteristics were notable for higher cost quintiles containing younger patients with lower CHADS-VASc scores, both for outpatients and inpatients (Table 1) .
At the patient level, the total cohort's median encounter cost was 58.6 ± 9.4
<0.001
Sex (female) 
Length of stay (mean ± SD)
<0.001 no significant trends across cost quintiles for 1-year repeat procedures (Table 3) . 18.8%, P value = 0.002; Table 3 ).
TA B L E 2 Patient and facility level cost variation
In multivariate analyses, among outpatient procedures, every Table S2 ).
DISCUSSION
We found wide patient and facility-level variation in cost of catheter ablation for AF across the US healthcare system with a 17.2-fold and 3.6-fold difference between the total cohort's 10th and 90th percentile encounter cost, respectively. After controlling for covariates, outpatient encounter cost was associated with modestly improved downstream healthcare utilization.
To our knowledge, this is the first examination of cost variability of catheter ablation for AF. Facility cost variation of percutaneous coronary intervention (PCI) was previously examined within the VA Health
Care System, with a 5-fold cost difference observed between the lowest and highest VA facilities' mean encounter cost (defined as all costs within 7 days of PCI). Greater variation was found in risk adjusted 1-year cost as compared to risk adjusted 1-year mortality, suggesting that there may be significant potential for cost reduction. 7 We found greater facility level encounter cost variation for AF ablation as compared to the PCI study, which may be due to several factors. Greater heterogeneity in AF ablation technique and equipment may contribute to the larger cost variation as compared to PCI. In fact, ablation has more modifier and add-on procedural billing codes as compared to
PCI. An analysis of AF ablation equipment costs to the hospital by Winkle et al. found that equipment cost can vary between $6,637 to $22,284. 15 However, even if this variation was tripled, it would not account for wide range in cost variation across all sites, suggesting that other factors account for most of the observed variation.
Previous cost-effectiveness analyses of AF ablation have found incremental cost-effectiveness ratios close to willingness-to-pay thresholds ($50,000 per quality-adjusted life year), suggesting that AF ablation is cost-effective in carefully selected patients. 12, [16] [17] [18] [19] [20] [21] [22] However, these analyses are highly dependent on input variables (e.g., time horizon, patient characteristics, procedural success rate, and procedure cost). Our facility-level median encounter costs (outpatient: Unwarranted cost variability may be reduced by addressing knowledge gaps in the AF ablation literature, reducing technique and equipment heterogeneity. However, thoughtful and evidence driven health policy reforms have greater potential to reduce unwarranted cost variation and increase value. To date, lack of consensus on strategy has hindered policy reform. 27 Policies supporting reduction of payment rates to high-spending regions have been criticized as penalizing institutions providing high value care in high-spending regions. 27, 28 While policies incentivizing high-value care (e.g., accountable care organizations and bundled payments) have been criticized for inaccurately measuring value of care. 27 Further exploration of the complicated relationship between cost and outcomes of AF ablation is warranted to guide policy reform efforts targeted at improving procedure value.
The Affordable Care Act supports bundled payment and readmission penalties, which could incentivize reducing complications and the associated cost of complications. However, procedure availability could be limited if facilities make economically driven decisions to defer or not offer ablation to more complex or high-risk patients. Additionally, bundling payments may de-incentivize uptake and development of novel and potentially more efficacious ablation approaches, which themselves may have operator and facility learning curves. 29, 30 Our study has multiple limitations. First, zip code anonymity prevented controlling for socioeconomic factors that may account for some of the cost variability as well as practice variation that could account for some of the decreased hospitalization rates. Second, site aggregation based on 5-digit zip codes could have combined multiple hospitals into a single aggregate site in some dense, metropolitan areas. However, although this could affect variation within the aggregated site, variation across sites would decrease and bias toward the null, and this would not affect patient-level analysis. Third, in order to properly ascertain baseline comorbidities and outcomes, we had to condition cohort inclusion based on pre-and postablation continuous health plan enrollment, which could introduce selection bias if high-or low-healthcare utilizers were differentially excluded. Fourth, we were unable to extract details on specific ablation equipment, technique or AF severity, thereby preventing us from comparing cost and outcomes of different ablation strategies (e.g., pulmonary vein isolation vs. other strategies). Finally, although we used a previously developed approach to identify AF ablation with high specificity, individual case misclassification is possible, although it would not be expected to drive site-level results.
CONCLUSION
We found wide patient and facility-level variation in cost of catheter ablation for AF. Although median costs of AF ablation are below amounts used in prior cost-effectiveness studies that demonstrated good value, the large facility variation in cost suggests that there may be opportunities for cost reduction.
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